ACTION: Stimulates the release of insulin-like growth factor-1, abbreviated IGF-1, from the liver and other tissues.
Growth hormone deficiencies, such as Turner’s syndrome
Growth hormone deficiency in adults to increase lean muscle mass
AIDS wasting syndrome
Fatality in PWS Clients
Severe respiratory impairment
Closed epiphyses in children
Glucocorticoids and adrenocorticotropic hormone counteract growth-stimulating effects.
Thyroid hormones, estrogens, and androgens promote epiphyseal clo- sure.
Monitor blood glucose levels.
Give IM or subcutaneously (preferable).
Dosage is based on weight
Given daily or several times a wee
Pediatric Clients: Obtain baseline height, weight, thyroid function, and growth hormone levels and monitor monthly; yearly X-rays of long bones
When reconstituting the drug, rotate the vial gently and do not shake it
Inject subcutaneously into the abdomen and thighs and rotate sites.
Discontinue treatment prior to epiphyseal closure in children.
Injection site should be rotated.
Chronic renal failure